Advanced Therapeutics (ADVTX) has announced that Fibrinoplate-S has shown efficacy in reducing the bleeding in animals exposed to extreme doses of radiation. Reportedly in preclinical trials, Fibrinoplate-S reduced
America Stem Cell (ASC) has been awarded $2.5 million from the State of Texas Emerging Technology Fund (ETF). This investment would enable ASC to accelerate the development of
Vidacare has closed a $7.6 million private equity Series D1 financing. The financing would be used to launch Vidacare’s hematology/oncology product – OnControl Bone Marrow System, and OnControl
Maxygen has completed its phase IIa clinical study in breast cancer patients, in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia (CIN). Phase IIa study were
Johnson & Johnson has reported sales of $15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational
Actavis has launched Irinotecan, a cancer drug, in the UK, France, the Netherlands, Germany, Austria and Sweden on 13 and 14 July. The patents expired on 12 and
Xoma has reported positive results from single dose and multiple dose subcutaneous arms of the randomized, placebo-controlled US phase 1 clinical trial of Xoma 052, in type 2
Watson Pharmaceuticals has received a Complete Response Letter from FDA on its New Drug Application (NDA) for Trelstar 22.5mg (triptorelin pamoate for injectable suspension). Its a 24-week formulation
Biomet has reported a net loss of $749.2 million for fiscal year 2009, as compared to $1 billion for fiscal year 2008. The company has reported a net
Noven Pharmaceuticals and Hisamitsu Pharmaceutical have entered into a merger agreement. Hisamitsu has proposed to acquire Noven for total cash consideration of approximately $428 million or $16.50 per
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.